Translate page

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

Resistant Pediatric CML

  • Nirmalya Roy Moulik
  • Nirmalya Roy Moulik's Avatar Topic Author
3 days 19 hours ago #2131 by Nirmalya Roy Moulik
Replied by Nirmalya Roy Moulik on topic Resistant Pediatric CML
My response wouldn't differ much from the adult experts- I would continue the asciminib for a longer period before making any changes immediately. Of course, BMT should be considered, as this child has a high chance of treatment failure over time.
Also, the importance of the ASXL1 mutation in children with CML is less clear than in adults.
Hope this helps.
  • Nobuko Hijiya
  • Nobuko Hijiya's Avatar Topic Author
1 day 16 hours ago #2132 by Nobuko Hijiya
Replied by Nobuko Hijiya on topic Resistant Pediatric CML
Having the pending result from 7 months, I would give her a little more time with asciminib, once daily. Asciminib decreased the FISH from 4 months to 6 months.
It would be a good idea to at least consult BMT service and look at the mutation analysis. But I would give her a little more time, a couple of months, as long as she is in CP and BCR::ABL1 is decreasing. The best timing of BMT is not very clear. As long as the patient is in CP, I think it is OK. ASXL1 mutation is known to have less favourable outcome in adults. We do not have data in peds yet.
  • Jeff Lipton
  • Jeff Lipton's Avatar Topic Author
1 day 16 hours ago #2133 by Jeff Lipton
Replied by Jeff Lipton on topic Resistant Pediatric CML
For whatever reason, this young woman is resistant with very little response - this may be a mutation or clonal progression, but that does not matter. The longer that is waited, there is a chance that she will lose the only treatment that will likely benefit her in the long run, ie an allograft. Playing around with TKIs in combination or not runs the risk that she will blast off. Best result with an allograft is NOW, if a donor is available. Debulking with a TKI will not improve things. Hydroxyurea if necessary and transplant. I am concerned that she was on the cusp of what we used to call accelerated disease at diagnosis - basophils worry me here. Waiting here is a ticking clock.
Moderators: Nicolaarlene